US › Healthcare

Sionna Therapeutics, Inc. Common Stock (SION)

US · Healthcare · Biotechnology

$7.18+1.99%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-29.9M

EPS

$-0.66

EPS estimate

$-0.64

EPS came in at -0.66 against a street estimate of -0.64 — a miss of 3.1%.

Key statistics

Market cap

$344.0M

Forward P/E

0.0

P/B

1.28

Book value

$5.88

EPS (TTM)

$-2.18

52-week high

$54.97

52-week low

$4.01

50-day MA

$28.39

200-day MA

$36.82

Analyst view

Analysts rate Sionna Therapeutics, Inc. Common Stock a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $20.86.

Shareholding

Insiders

6.84%

Institutions

107.20%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	21.91%
TPG GP A, LLC	14.37%
Orbimed Advisors LLC	7.81%
Viking Global Investors LP	7.07%
Atlas Venture Life Science Advisors, LLC	6.63%
Enavate Sciences GP, LLC	5.48%
Adage Capital Partners Gp LLC	3.54%
JPMorgan Chase & Co	3.24%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sionna Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.